Attovia Therapeutics
PrivateLast Round
Series C
Apr 15, 2025
Total Funding Raised
$315M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Attovia Therapeutics is a biotechnology company that develops precision biologics and multispecific therapeutics for immune-mediated diseases and oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Attovia Therapeutics Comparables
Compare Attovia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Santa Ana Bio | 79% | |
| Bambusa Therapeutics | 79% | |
| Apogee Therapeutics | 77% |
Attovia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 15, 2025 | ||||
| Series B | May 9, 2024 | ||||
| Series A | Feb 8, 2024 | ||||
| Series A | Jun 20, 2023 |
Key People
Founding team and executive leadership
Attovia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C, Series B |
| Redmile Group | Series B |
| Mirae Asset | Series C |
| Cormorant Asset Management | Series C, Series B |
| Vida Ventures | Series C |
| Deep Track Capital | Series C |
| Frazier Life Sciences | Series C, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 154% MoM.
- May 13, 2025
Partnered with SciNeuro Pharmaceuticals on a neurology target.
Recent news
Latest coverage and updates
- receives_financingAug 6, 2026
Attovia Therapeutics, Inc. received financing of $332M in IPO on Aug 5th '26.
- is_developingAug 4, 2026
Attovia Therapeutics, Inc. is developing biologic therapies for immune-mediated diseases on Jul 1st '23.
- receives_financingAug 4, 2026
Attovia Therapeutics, Inc. received financing of $289M in IPO on Mar 31st '26.
- receives_financingJul 31, 2026
Attovia Therapeutics, Inc. was planning to receive financing of $182M in public offering on Jul 27th '26.
- identified_as_competitor_ofJul 15, 2026
Attovia identified as competitor of Sanofi on Jul 15th '26.
Attovia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Attovia Therapeutics's valuation, stock price, and market status.
Is Attovia a public or private company?
Attovia is a private company.
What is the current stock price of Attovia?
Attovia is a private company with no public stock price. No recent secondary market data is available.
How much is Attovia worth (valuation)?
Valuation information for Attovia is not publicly available.
Can I buy Attovia stock?
Attovia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Attovia's last funding round?
Attovia's most recent funding round was Series C on April 15, 2025.
Who are the main investors in Attovia?
Key investors in Attovia include Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives.
Will Attovia IPO soon?
No public IPO plans have been announced for Attovia.
How can I track Attovia secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Attovia's secondary market activity and sign up for updates.